Vaxcyte, Inc. (MUN:5VA)
Germany · Delayed Price · Currency is EUR | Market Cap | 7.79B +117.9% |
| Revenue (ttm) | n/a |
| Net Income | -931.55M |
| EPS | -6.69 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 52.50 |
| Previous Close | 53.50 |
| Day's Range | 52.50 - 52.50 |
| 52-Week Range | 25.80 - 53.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Vaxcyte
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused b... [Read more]
News
Vaxcyte reports Q2 EPS ($1.97), consensus ($2.10)
“With the VAX-31 OPUS-1, OPUS-2 and OPUS-3 Phase 3 trials and the VAX-31 Phase 2 infant study fully enrolled, we expect a series of meaningful clinical study readouts across our…
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline...
Vaxcyte Slides: Investor presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Vaxcyte Quarterly report: Q2 2026
Vaxcyte has published its Q2 2026 quarterly earnings report on August 5, 2026.
Vaxcyte Earnings release: Q2 2026
Vaxcyte released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Vaxcyte to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host on...
Vaxcyte Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and an advisory vote on executive compensation, with all proposals passing by a wide margin. No questions were raised by shareholders during the meeting or Q&A.
Vaxcyte Transcript: Jefferies Global Healthcare Conference 2026
The discussion highlighted a robust pipeline leveraging a proprietary platform, with pivotal phase III adult pneumococcal vaccine data expected soon and a strong competitive position as rivals exit the field. Regulatory strategy focuses on totality of data, and a new Group A Strep program addresses a major unmet need.
Vaxcyte doses first participant in VAX-A1 study
Vaxcyte (PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1, the company’s investigational prophylactic vaccine candidate for the prevention of...
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus
Vaxcyte Slides: Corporate presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Vaxcyte Transcript: Bank of America Global Healthcare Conference 2026
VAX-31's phase III program is fully enrolled, with pivotal data expected in Q4 2024. The vaccine targets 31 serotypes, aiming for broader coverage and robust immune responses compared to current standards. Regulatory and commercial preparations are advancing, with market launch targeted for late 2025.
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
The company said, “With the recent completion of OPUS-3 enrollment, our OPUS-1, OPUS-2 and OPUS-3 adult Phase 3 trials are now fully enrolled, and we remain on track to deliver…
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte Quarterly report: Q1 2026
Vaxcyte has published its Q1 2026 quarterly earnings report on May 6, 2026.
Vaxcyte Earnings release: Q1 2026
Vaxcyte released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Vaxcyte Slides: Corporate presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Vaxcyte Proxy statement: Proxy filing
Vaxcyte filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Vaxcyte Proxy statement: Proxy filing
Vaxcyte filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Vaxcyte Transcript: 25th Annual Needham Virtual Healthcare Conference
Upcoming 12–15 months will see pivotal data from adult and infant VAX-31 studies, with a BLA filing targeted by end of next year and potential approval in 2028. Market growth is driven by expanded adult vaccination and global recommendations, while strong financials support continued development.
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside...
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
Vaxcyte (PCVX) announced the completion of enrollment in the VAX-31 OPUS-1 Phase 3 pivotal, noninferiority trial with approximately 4,000 participants and the OPUS-2 Phase 3 trial evaluating VAX-31 co...
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capva...
Vaxcyte Slides: Corporate presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on March 23, 2026.
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
The company states: “Vaxcyte (PCVX) announced the publication of results from the positive VAX-31 adult Phase 1/2 clinical study in the journal The Lancet Infectious Diseases. The study evaluated the…